Answers are grounded in this paper and cite their sources.
Summary Background Unlike acetaminophen, nonsteroidal anti‐inflammatory drugs (NSAIDs) have generally been thought to be associated with increased risk of IBD exacerbation. Aim To carry out a systematic review and meta‐analysis of previous studies examining the association between acetaminophen and NSAIDs including cyclooxygenase (COX‐2) inhibitors use, and risk of Crohn's disease (CD) and ulcerative colitis (UC) exacerbation. Methods We identified published manuscripts and abstracts through 1 March 2017 by systematic search of Medline, Embase, Cochrane and other trial registries. Quality assessment was done using Newcastle‐Ottawa scale and random‐effect meta‐analysis using pooled relative risks (RRs) and 95% CIs were calculated. Results Eighteen publications between years 1983 and 2016 were identified. For the meta‐analysis, pooled RRs of disease exacerbation with NSAIDs use were (1.42, 95% CI, 0.65‐3.09), I 2 = 60.3% for CD, and (1.52, 95% CI, 0.87‐2.63), I 2 = 56.1% for UC. The corresponding values for acetaminophen use were (1.40, 95% CI, 0.96‐2.04), I 2 = 45.6% for UC, and (1.56, 95% CI, 1.22‐1.99), I 2 = 0.0% for IBD. Sensitivity analyses limited to studies with low risk of bias showed a significantly increased risk of CD exacerbation (1.53, 95% CI, 1.08‐2.16) but not UC (0.94, 95% CI, 0.36‐2.42) with NSAIDs use. Conclusions Contrary to generally accepted belief, we did not find a consistent association between NSAIDs use and risk of CD and UC exacerbation. There was also no consistent evidence for association with acetaminophen although further studies are needed.
No takes yet. Share an insight, caveat, or question.
Moninuola et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: